Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with Herpes Zoster

PharmacoEconomics

Volumn 27, Issue 12, 2009, Pages 1005-1016

  Lieu, Tracy A ^a,b   Ray, G Thomas ^c   Ortega Sanchez, Ismael R ^d   Kleinman, Ken ^a   Rusinak, Donna ^a   Prosser, Lisa A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DIVISION OF RESEARCH   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COMMUNITY; COST EFFECTIVENESS ANALYSIS; EXPERIENCE; FEMALE; GENDER; HEALTH STATUS; HEALTH SURVEY; HERPES ZOSTER; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; PAIN PARAMETERS; PATIENT ATTITUDE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SOCIAL STATUS; WILLINGNESS TO PAY;

AGED; COMMUNITY-INSTITUTIONAL RELATIONS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; FINANCING, PERSONAL; HEALTH CARE SURVEYS; HEALTH STATUS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PATIENT PREFERENCE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; TREATMENT OUTCOME; UNITED STATES;

EID: 73549108099     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11314000-000000000-00000     Document Type: Article

References (33)

1. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20 (3): 332-342
2. BuxtonM. Looking for willingness-to-pay (WTP) threshold for a QALY: does it make sense? A practical view. ISPOR Connections 2007 Aug 15; 13 (4): 9-11
3. Gyrd-Hansen D. Looking for willingness to pay (WTP) threshold for a QALY: does it make sense? A critical view. ISPOR Connections 2007 Aug 15; 13 (4): 5-8
4. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008 Feb 14; 358 (7): 661-663
5. Grosse S. Assessing cost-effectiveness in healthcare: history of the $50 000 per QALY threshold. ExpertRev Pharmacoeconomics Outcomes Res 2008; 8: 2165-2178
6. Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19 (2): 92-109
7. Weinstein M. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46 (4): 343-345
8. Byrne MM, O'Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 2005 Nov-Dec; 25 (6): 655-666
9. King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005; 25 (6): 667-677
10. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ 2003 Dec; 12 (12): 1049-1060
11. Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008; 26 (3): 235-249
12. International classification of diseases. 9th ed. Geneva: World Health Organization, 1977
13. Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University, 1996
14. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993
15. Baron J, Asch DA, Fagerlin A, et al. Effect of assessment method on the discrepancy between judgments of health disorders people have and do not have: a web study. Med Decis Making 2003; 23 (5): 422-434
16. Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003; 12 (6): 599-607
17. Van Houtven G, Powers J, Jessup A, et al. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ 2006 Aug; 15 (8): 775-795
18. Messonnier M, Zhou F. Review of economic studies of varicella zoster vaccine [oral presentation]. Advisory Committee on Immunization Practices (ACIP) Meeting; 2006 Oct 25; Atlanta (GA)
19. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006 Sep 5; 145 (5): 317-325
20. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007May 15; 44 (10): 1280-1288
21. Pellissier J. Evaluation of zoster vaccine cost-effectiveness [oral presentation]. Advisory Committee of Immunization Practices (ACIP) Meeting; 2006 Jun 30; Atlanta (GA)
22. Ortega-Sanchez IR. Projected cost-effectiveness of vaccinating US elderly to prevent shingles [oral presentation]. Advisory Committee for Immunization Practices (ACIP) Meeting; 2006 Jun 30; Atlanta (GA)
23. Pellissier JM, Brisson M, Levin MJ. Evaluation of the costeffectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007 Nov 28; 25 (49): 8326-8337
24. Ho AMH, Coplan P, Lee A, et al. Cost-effectiveness of varicella zoster vaccination in older adults [abstract]. Can J Anethesia 2006; 53 Suppl. 1: 26394
25. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008 Jun 6; 57 (RR-5): 1-30; quiz CE2-4
26. Braithwaite RS, Meltzer DO, King Jr JT, et al. What does the value of modern medicine say about the $50 000 per qualityadjusted life-year decision rule? Med Care 2008; 46 (4): 349-356
27. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005; 23 (5): 423-432
28. Smith RD, Richardson J. Can we estimate the 'social' value of a QALY? Four core issues to resolve. Health Policy 2005 Sep 28; 74 (1): 77-84
29. Hammitt J, Haninger K. Willingness to pay for food safety: sensitivity to duration and severity of illness. Amer J Agr Econ 2007; 89 (5): 1170-1175
30. Hammitt J, Graham JD. Willingness to pay for health protection: inadequate sensitivity for probability? J Risk Uncertainty 1999; 18 (1): 33-62
31. Oliver A, Sorenson C. Importance of preference reversals in the valuation of health and healthcare. Expert Rev Pharmacoeconomics Outcomes Res 2008; 8 (2): 95-99
32. Krosnick J, LinChiat C. A comparison of the random digit dialing telephone survey methodology as implemented by Knowledge Networks and Harris Interactive [presentation]. Conference of the American Association for Public Opinion Research; 2001 May 17-20; Montreal (QC)
33. Lenert LA. The reliability and internal consistency of an Internet-capable computer program formeasuring utilities. Qual Life Res 2000; 9 (7): 811-817